| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyBiologicalProcess | regulation of cyclin-dependent protein serine/threonine kinase activity | 5.95e-07 | 96 | 105 | 7 | GO:0000079 | |
| GeneOntologyBiologicalProcess | regulation of cyclin-dependent protein kinase activity | 7.86e-07 | 100 | 105 | 7 | GO:1904029 | |
| GeneOntologyBiologicalProcess | negative regulation of cyclin-dependent protein serine/threonine kinase activity | 1.37e-05 | 29 | 105 | 4 | GO:0045736 | |
| GeneOntologyBiologicalProcess | regulation of transferase activity | IPO5 IPO7 ERN1 RGPD1 CBL RYK CCNB1 BMI1 RASGRP1 LATS1 LATS2 CCNB2 SETD7 PLEC CDC25C | 1.48e-05 | 810 | 105 | 15 | GO:0051338 |
| GeneOntologyBiologicalProcess | negative regulation of cyclin-dependent protein kinase activity | 1.57e-05 | 30 | 105 | 4 | GO:1904030 | |
| GeneOntologyBiologicalProcess | regulation of kinase activity | IPO5 IPO7 ERN1 RGPD1 CBL RYK CCNB1 RASGRP1 LATS1 LATS2 CCNB2 PLEC CDC25C | 4.56e-05 | 686 | 105 | 13 | GO:0043549 |
| GeneOntologyBiologicalProcess | negative regulation of protein modification process | 6.03e-05 | 512 | 105 | 11 | GO:0031400 | |
| GeneOntologyBiologicalProcess | inner cell mass cell fate commitment | 7.68e-05 | 3 | 105 | 2 | GO:0001827 | |
| GeneOntologyBiologicalProcess | inner cell mass cellular morphogenesis | 7.68e-05 | 3 | 105 | 2 | GO:0001828 | |
| GeneOntologyBiologicalProcess | regulation of protein serine/threonine kinase activity | 8.99e-05 | 358 | 105 | 9 | GO:0071900 | |
| GeneOntologyCellularComponent | SWI/SNF superfamily-type complex | 1.08e-04 | 96 | 102 | 5 | GO:0070603 | |
| GeneOntologyCellularComponent | catalytic step 2 spliceosome | 1.13e-04 | 97 | 102 | 5 | GO:0071013 | |
| GeneOntologyCellularComponent | nuclear protein-containing complex | IPO5 ESS2 IPO7 RGPD1 MCM2 XPA RBM48 TRRAP EFTUD2 BMI1 BPTF SF3B1 CHD5 SF3B6 MTREX MGA HDAC2 | 3.45e-04 | 1377 | 102 | 17 | GO:0140513 |
| GeneOntologyCellularComponent | ATPase complex | 4.27e-04 | 129 | 102 | 5 | GO:1904949 | |
| GeneOntologyCellularComponent | spliceosomal complex | 6.54e-04 | 215 | 102 | 6 | GO:0005681 | |
| MousePheno | increased central memory CD4-positive, alpha-beta T cell number | 9.21e-06 | 24 | 79 | 4 | MP:0010841 | |
| MousePheno | abnormal central memory CD4-positive, alpha-beta T cell number | 2.32e-05 | 30 | 79 | 4 | MP:0012771 | |
| MousePheno | abnormal central memory CD4-positive, alpha-beta T cell morphology | 2.32e-05 | 30 | 79 | 4 | MP:0010840 | |
| MousePheno | increased central memory CD8 positive, alpha-beta T cell number | 4.33e-05 | 35 | 79 | 4 | MP:0010847 | |
| MousePheno | increased effector memory CD4-positive, alpha-beta T cell number | 8.16e-05 | 41 | 79 | 4 | MP:0010844 | |
| MousePheno | abnormal central memory CD8-positive, alpha-beta T cell number | 8.98e-05 | 42 | 79 | 4 | MP:0012772 | |
| MousePheno | abnormal central memory CD8 positive, alpha-beta T cell morphology | 8.98e-05 | 42 | 79 | 4 | MP:0010846 | |
| MousePheno | abnormal effector memory CD4-positive, alpha-beta T cell number | 1.52e-04 | 48 | 79 | 4 | MP:0012770 | |
| MousePheno | abnormal effector memory CD4-positive, alpha-beta T cell morphology | 1.52e-04 | 48 | 79 | 4 | MP:0010843 | |
| MousePheno | decreased CD8-positive, naive alpha-beta T cell number | 2.08e-04 | 52 | 79 | 4 | MP:0013435 | |
| MousePheno | abnormal CD4-positive, alpha-beta memory T cell morphology | 2.59e-04 | 55 | 79 | 4 | MP:0010834 | |
| Domain | ARM-type_fold | 1.96e-05 | 339 | 104 | 10 | IPR016024 | |
| Domain | NYAP1/NYAP2 | 3.07e-05 | 2 | 104 | 2 | IPR026722 | |
| Domain | NYAP_C | 3.07e-05 | 2 | 104 | 2 | IPR029353 | |
| Domain | NYAP_C | 3.07e-05 | 2 | 104 | 2 | PF15452 | |
| Domain | Znf_RING/FYVE/PHD | UBE4B PCLO ASH1L RNF213 CBL UBR7 BMI1 BPTF PIAS3 CHD5 IRF2BPL | 5.01e-05 | 459 | 104 | 11 | IPR013083 |
| Domain | IMPORTIN_B_NT | 5.84e-05 | 14 | 104 | 3 | PS50166 | |
| Domain | Cse1 | 9.18e-05 | 3 | 104 | 2 | PF08506 | |
| Domain | Cse1 | 9.18e-05 | 3 | 104 | 2 | IPR013713 | |
| Domain | Importin-beta_N | 1.08e-04 | 17 | 104 | 3 | IPR001494 | |
| Domain | ARM-like | 1.34e-04 | 270 | 104 | 8 | IPR011989 | |
| Pathway | KEGG_MEDICUS_REFERENCE_CDC25_CELL_CYCLE_G2_M | 2.21e-05 | 10 | 82 | 3 | M47572 | |
| Pathway | KEGG_MEDICUS_PATHOGEN_HIV_VPR_TO_CDC25_CELL_CYCLE_G2M | 3.03e-05 | 11 | 82 | 3 | M47573 | |
| Pathway | REACTOME_POLO_LIKE_KINASE_MEDIATED_EVENTS | 1.01e-04 | 16 | 82 | 3 | M26971 | |
| Pathway | KEGG_MEDICUS_PATHOGEN_HIV_VPR_TO_WEE1_CELL_CYCLE_G2M | 3.30e-04 | 5 | 82 | 2 | M49022 | |
| Pathway | REACTOME_ACTIVATION_OF_NIMA_KINASES_NEK9_NEK6_NEK7 | 3.30e-04 | 5 | 82 | 2 | MM14918 | |
| Pathway | REACTOME_G2_M_DNA_REPLICATION_CHECKPOINT | 3.30e-04 | 5 | 82 | 2 | M27669 | |
| Pathway | REACTOME_G2_M_DNA_REPLICATION_CHECKPOINT | 3.30e-04 | 5 | 82 | 2 | MM15382 | |
| Pathway | REACTOME_CYCLIN_A_B1_B2_ASSOCIATED_EVENTS_DURING_G2_M_TRANSITION | 3.98e-04 | 25 | 82 | 3 | M808 | |
| Pathway | REACTOME_CYCLIN_A_B1_B2_ASSOCIATED_EVENTS_DURING_G2_M_TRANSITION | 3.98e-04 | 25 | 82 | 3 | MM15379 | |
| Pubmed | IPO5 TPT1 ZC3H14 SET IPO7 THUMPD1 RNF213 MCM2 CHD9 XPA PHAX TRRAP BPTF UBA1 SF3B1 DIAPH1 IRF2BPL PLEC MTREX IMMT HDAC2 | 3.57e-12 | 1014 | 106 | 21 | 32416067 | |
| Pubmed | A high-throughput approach for measuring temporal changes in the interactome. | ATG5 IPO5 SET IPO7 MYO1E UBE4B THUMPD1 RANBP6 IREB2 MCM2 PHAX UBR7 EFTUD2 UBA1 SETSIP DIAPH1 IRF2BPL PLEC DYNC1LI2 | 8.01e-08 | 1455 | 106 | 19 | 22863883 |
| Pubmed | Identifying biological pathways that underlie primordial short stature using network analysis. | IPO5 ZC3H14 IPO7 MCM2 TRRAP F5 EFTUD2 BPTF UBA1 SF3B1 SF3B6 PLEC MTREX MGA IMMT HDAC2 | 8.77e-08 | 1024 | 106 | 16 | 24711643 |
| Pubmed | Proteome-scale mapping of binding sites in the unstructured regions of the human proteome. | 8.82e-08 | 430 | 106 | 11 | 35044719 | |
| Pubmed | LCP1 preferentially binds clasped αMβ2 integrin and attenuates leukocyte adhesion under flow. | 1.08e-07 | 344 | 106 | 10 | 30333137 | |
| Pubmed | IPO5 SET IPO8 IPO7 RANBP6 MCM2 MRPL45 PHAX TRRAP CCNB1 EFTUD2 UBA1 SF3B1 SETSIP MTREX IMMT MRPL1 HDAC2 | 1.15e-07 | 1335 | 106 | 18 | 29229926 | |
| Pubmed | Direct interaction between hnRNP-M and CDC5L/PLRG1 proteins affects alternative splice site choice. | IPO5 IPO7 DOCK8 CCNB1 EFTUD2 SF3B1 VPS33B SF3B6 DIAPH1 PLEC MTREX DYNC1LI2 | 2.27e-07 | 582 | 106 | 12 | 20467437 |
| Pubmed | TPT1 ZC3H14 SET ESS2 IPO8 IPO7 DOCK8 CHD9 TRRAP CCNB1 BPTF UBA1 SF3B6 C1orf52 MTREX HDAC2 | 2.39e-07 | 1103 | 106 | 16 | 34189442 | |
| Pubmed | 2.74e-07 | 5 | 106 | 3 | 18591933 | ||
| Pubmed | The in vivo Interaction Landscape of Histones H3.1 and H3.3. | IPO5 ESS2 IPO7 CHD9 PHAX TRRAP UBR7 BMI1 BPTF CHD5 MGA HDAC2 | 3.62e-07 | 608 | 106 | 12 | 36089195 |
| Pubmed | 5.47e-07 | 6 | 106 | 3 | 7474100 | ||
| Pubmed | IPO5 IPO8 IPO7 MCM2 EFTUD2 UBA1 SF3B1 DIAPH1 PLEC MTREX IMMT HDAC2 | 6.01e-07 | 638 | 106 | 12 | 33239621 | |
| Pubmed | Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. | 7.59e-07 | 327 | 106 | 9 | 15592455 | |
| Pubmed | IPO5 ZC3H14 ESS2 IPO8 DOCK8 MCM2 NBEA UBA1 SF3B6 PLEC PPIP5K2 MGA VAV1 HDAC2 | 7.85e-07 | 916 | 106 | 14 | 32203420 | |
| Pubmed | IPO5 IPO8 IPO7 RANBP6 TBC1D9 EFTUD2 SF3B1 SF3B6 SEC63 MGA ACAP2 IMMT | 8.17e-07 | 657 | 106 | 12 | 36180527 | |
| Pubmed | 9.55e-07 | 7 | 106 | 3 | 11682607 | ||
| Pubmed | 9.55e-07 | 7 | 106 | 3 | 9520381 | ||
| Pubmed | IPO5 IPO7 CCNB1 EFTUD2 VPS33B DIAPH1 SETD7 MTREX IMMT DYNC1LI2 HDAC2 | 1.20e-06 | 560 | 106 | 11 | 35241646 | |
| Pubmed | TIF1γ inhibits lung adenocarcinoma EMT and metastasis by interacting with the TAF15/TBP complex. | 1.35e-06 | 179 | 106 | 7 | 36261009 | |
| Pubmed | NANOG-dependent function of TET1 and TET2 in establishment of pluripotency. | 1.36e-06 | 27 | 106 | 4 | 23395962 | |
| Pubmed | Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation. | 1.40e-06 | 180 | 106 | 7 | 30110629 | |
| Pubmed | 1.52e-06 | 8 | 106 | 3 | 27114554 | ||
| Pubmed | 14-3-3 theta binding to cell cycle regulatory factors is enhanced by HIV-1 Vpr. | 1.52e-06 | 8 | 106 | 3 | 18445273 | |
| Pubmed | TPT1 SET PCDHGA1 PCLO ASH1L RGPD1 PTPN21 BPTF LATS1 SF3B1 LATS2 SETSIP CHD5 PLEC PPIP5K2 IMMT HDAC2 | 1.71e-06 | 1442 | 106 | 17 | 35575683 | |
| Pubmed | ATG5 IPO5 MYO1E UBE4B ASH1L APBA1 CHD9 NBEA REV3L RYR3 NAA25 SF3B1 PIAS3 PLEC IMMT ECE2 | 1.78e-06 | 1285 | 106 | 16 | 35914814 | |
| Pubmed | SET THUMPD1 MCM2 CHD9 MRPL45 PHAX DNAH7 EFTUD2 UBA1 SF3B1 CHD5 SF3B6 MTREX IMMT HDAC2 | 2.27e-06 | 1153 | 106 | 15 | 29845934 | |
| Pubmed | 2.88e-06 | 494 | 106 | 10 | 26831064 | ||
| Pubmed | Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function. | ATG5 IPO7 UBE4B TUT7 MCM2 TRRAP EFTUD2 UBA1 SF3B1 VPS33B SF3B6 DIAPH1 PLEC MTREX MGA IMMT | 3.44e-06 | 1353 | 106 | 16 | 29467282 |
| Pubmed | Large-scale characterization of HeLa cell nuclear phosphoproteins. | UBE4B MCM2 TRRAP TBC1D9 EFTUD2 BPTF UBA1 LATS1 SF3B1 IRF2BPL PLEC DYNC1LI2 | 4.42e-06 | 774 | 106 | 12 | 15302935 |
| Pubmed | IPO5 ZC3H14 IPO7 TUT7 TRRAP BPTF SF3B1 PLEC MTREX IMMT HDAC2 | 5.21e-06 | 653 | 106 | 11 | 22586326 | |
| Pubmed | GRWD1 regulates ribosomal protein L23 levels via the ubiquitin-proteasome system. | 5.44e-06 | 221 | 106 | 7 | 29991511 | |
| Pubmed | 5.93e-06 | 12 | 106 | 3 | 7494303 | ||
| Pubmed | Gain of Additional BIRC3 Protein Functions through 3'-UTR-Mediated Protein Complex Formation. | IPO5 SET IPO8 IPO7 DNAH10 PCLO MCM2 PLA2G15 EFTUD2 UBA1 SF3B1 VPS33B DIAPH1 MTREX SEC63 IMMT | 6.61e-06 | 1425 | 106 | 16 | 30948266 |
| Pubmed | 7.27e-06 | 549 | 106 | 10 | 38280479 | ||
| Pubmed | IPO5 SET IPO8 IPO7 MYO1E RANBP6 RNF213 MCM2 MRPL45 CCNB1 EFTUD2 SF3B1 IRF2BPL MTREX SEC63 MRPL1 | 7.53e-06 | 1440 | 106 | 16 | 30833792 | |
| Pubmed | PCGF homologs, CBX proteins, and RYBP define functionally distinct PRC1 family complexes. | 7.57e-06 | 41 | 106 | 4 | 22325352 | |
| Pubmed | 9.20e-06 | 2 | 106 | 2 | 25482410 | ||
| Pubmed | 9.20e-06 | 2 | 106 | 2 | 30671453 | ||
| Pubmed | 9.20e-06 | 2 | 106 | 2 | 20189481 | ||
| Pubmed | 9.20e-06 | 2 | 106 | 2 | 16432215 | ||
| Pubmed | 9.20e-06 | 2 | 106 | 2 | 32826458 | ||
| Pubmed | 5'-UTR and ORF elements, as well as the 3'-UTR regulate the translation of Cyclin. | 9.20e-06 | 2 | 106 | 2 | 32439164 | |
| Pubmed | 9.20e-06 | 2 | 106 | 2 | 29730476 | ||
| Pubmed | N-terminal truncation of Lats1 causes abnormal cell growth control and chromosomal instability. | 9.20e-06 | 2 | 106 | 2 | 23230145 | |
| Pubmed | Assignment of two human cell cycle genes, CDC25C and CCNB1, to 5q31 and 5q12, respectively. | 9.20e-06 | 2 | 106 | 2 | 1386342 | |
| Pubmed | LATS1 but not LATS2 represses autophagy by a kinase-independent scaffold function. | 9.20e-06 | 2 | 106 | 2 | 31848340 | |
| Pubmed | Functional analysis of the P box, a domain in cyclin B required for the activation of Cdc25. | 9.20e-06 | 2 | 106 | 2 | 8402895 | |
| Pubmed | Expression of LATS family proteins in ovarian tumors and its significance. | 9.20e-06 | 2 | 106 | 2 | 25841306 | |
| Pubmed | Proto-oncoprotein Vav interacts with c-Cbl in activated thymocytes and peripheral T cells. | 9.20e-06 | 2 | 106 | 2 | 9200440 | |
| Pubmed | Ligand binding induces Cbl-dependent EphB1 receptor degradation through the lysosomal pathway. | 9.20e-06 | 2 | 106 | 2 | 18034775 | |
| Pubmed | 9.20e-06 | 2 | 106 | 2 | 24026096 | ||
| Pubmed | 9.20e-06 | 2 | 106 | 2 | 38241547 | ||
| Pubmed | Association analysis between SNPs in LATS1 and LATS2 and non-cardia gastric cancer. | 9.20e-06 | 2 | 106 | 2 | 32423384 | |
| Pubmed | Deletion of Lats1/2 in adult kidney epithelia leads to renal cell carcinoma. | 9.20e-06 | 2 | 106 | 2 | 34060480 | |
| Pubmed | 9.20e-06 | 2 | 106 | 2 | 8375336 | ||
| Pubmed | Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma. | 9.20e-06 | 2 | 106 | 2 | 17049657 | |
| Pubmed | The kinetics of G2 and M transitions regulated by B cyclins. | 9.20e-06 | 2 | 106 | 2 | 24324638 | |
| Pubmed | Structural model of the p14/SF3b155 · branch duplex complex. | 9.20e-06 | 2 | 106 | 2 | 21062891 | |
| Pubmed | Lats1 and Lats2 are required for ovarian granulosa cell fate maintenance. | 9.20e-06 | 2 | 106 | 2 | 31268774 | |
| Pubmed | 9.20e-06 | 2 | 106 | 2 | 29074977 | ||
| Pubmed | The Hippo pathway regulates human megakaryocytic differentiation. | 9.20e-06 | 2 | 106 | 2 | 27786336 | |
| Pubmed | 9.20e-06 | 2 | 106 | 2 | 29074707 | ||
| Pubmed | Cell type-dependent function of LATS1/2 in cancer cell growth. | 9.20e-06 | 2 | 106 | 2 | 30531839 | |
| Pubmed | 9.20e-06 | 2 | 106 | 2 | 15746036 | ||
| Pubmed | Cbl enforces Vav1 dependence and a restricted pathway of T cell development. | 9.20e-06 | 2 | 106 | 2 | 21490975 | |
| Pubmed | 9.20e-06 | 2 | 106 | 2 | 30097513 | ||
| Pubmed | 9.20e-06 | 2 | 106 | 2 | 19799973 | ||
| Pubmed | LATS suppresses mTORC1 activity to directly coordinate Hippo and mTORC1 pathways in growth control. | 9.20e-06 | 2 | 106 | 2 | 32015438 | |
| Pubmed | Cbl-mediated ubiquitinylation and negative regulation of Vav. | 9.20e-06 | 2 | 106 | 2 | 12881521 | |
| Pubmed | 9.20e-06 | 2 | 106 | 2 | 25044019 | ||
| Pubmed | 9.20e-06 | 2 | 106 | 2 | 17533373 | ||
| Pubmed | Cyclin B2-null mice develop normally and are fertile whereas cyclin B1-null mice die in utero. | 9.20e-06 | 2 | 106 | 2 | 9539739 | |
| Pubmed | Overexpression of B-type cyclins alters chromosomal segregation. | 9.20e-06 | 2 | 106 | 2 | 11960377 | |
| Pubmed | Identifying the substrate proteins of U-box E3s E4B and CHIP by orthogonal ubiquitin transfer. | 9.77e-06 | 14 | 106 | 3 | 29326975 | |
| Pubmed | ATG5 is required for B cell polarization and presentation of particulate antigens. | ATG5 ZC3H14 TUT7 RGPD1 UBA1 SF3B6 PLEC MTREX IMMT VAV1 HDAC2 | 1.01e-05 | 701 | 106 | 11 | 30196744 |
| Pubmed | MYC multimers shield stalled replication forks from RNA polymerase. | ZC3H14 ESS2 MCM2 RYK EFTUD2 BPTF UBA1 SF3B1 SF3B6 PLEC MTREX SEC63 HDAC2 | 1.02e-05 | 989 | 106 | 13 | 36424410 |
| Pubmed | 1.04e-05 | 451 | 106 | 9 | 36168627 | ||
| Pubmed | Systematic Analysis of Human Protein Phosphatase Interactions and Dynamics. | 1.05e-05 | 573 | 106 | 10 | 28330616 | |
| Pubmed | Mutual regulation between OGT and XIAP to control colon cancer cell growth and invasion. | ATG5 IPO5 ESS2 THUMPD1 PHAX UBR7 CCNB1 UBA1 SETD7 DYNC1LI2 TBCEL | 1.05e-05 | 704 | 106 | 11 | 32994395 |
| Pubmed | Systematic analysis of human protein complexes identifies chromosome segregation proteins. | IPO5 SET IPO8 RGPD1 CCNB1 EFTUD2 UBA1 SF3B1 CCNB2 SF3B6 C1orf52 CDC25C DYNC1LI2 HDAC2 | 1.13e-05 | 1155 | 106 | 14 | 20360068 |
| Pubmed | Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. | ZC3H14 IPO8 MCM2 PHAX EFTUD2 UBA1 SF3B1 SETSIP SF3B6 MTREX ACAP2 | 1.20e-05 | 714 | 106 | 11 | 28302793 |
| Pubmed | Centrosome-related genes, genetic variation, and risk of breast cancer. | 1.57e-05 | 102 | 106 | 5 | 20508983 | |
| Pubmed | CTDP1 regulates breast cancer survival and DNA repair through BRCT-specific interactions with FANCI. | 1.73e-05 | 104 | 106 | 5 | 31240132 | |
| Pubmed | Transcription factor Foxp3 and its protein partners form a complex regulatory network. | 1.85e-05 | 370 | 106 | 8 | 22922362 | |
| Pubmed | Unbiased Identification of trans Regulators of ADAR and A-to-I RNA Editing. | 2.04e-05 | 271 | 106 | 7 | 32433965 | |
| Pubmed | Blocking an N-terminal acetylation-dependent protein interaction inhibits an E3 ligase. | 2.16e-05 | 495 | 106 | 9 | 28581483 | |
| Pubmed | MECP2 directly interacts with RNA polymerase II to modulate transcription in human neurons. | SET CHD9 MRPL45 TRRAP EFTUD2 BPTF SF3B1 SF3B6 PLEC PPIP5K2 SEC63 DYNC1LI2 HDAC2 | 2.61e-05 | 1082 | 106 | 13 | 38697112 |
| Pubmed | 2.63e-05 | 282 | 106 | 7 | 23667531 | ||
| Pubmed | IPO5 ZC3H14 SET IPO7 CHD9 EFTUD2 LATS1 SF3B1 DIAPH1 MTREX MGA IMMT DYNC1LI2 HDAC2 | 2.64e-05 | 1247 | 106 | 14 | 27684187 | |
| Pubmed | 2.76e-05 | 3 | 106 | 2 | 1717476 | ||
| Pubmed | 2.76e-05 | 3 | 106 | 2 | 10646609 | ||
| Pubmed | A FUS-LATS1/2 Axis Inhibits Hepatocellular Carcinoma Progression via Activating Hippo Pathway. | 2.76e-05 | 3 | 106 | 2 | 30308519 | |
| Pubmed | 2.76e-05 | 3 | 106 | 2 | 38141761 | ||
| Pubmed | Thrombosis Related ABO, F5, MTHFR, and FGG Gene Polymorphisms in Morbidly Obese Patients. | 2.76e-05 | 3 | 106 | 2 | 27999448 | |
| Pubmed | Fortilin binds IRE1α and prevents ER stress from signaling apoptotic cell death. | 2.76e-05 | 3 | 106 | 2 | 28550308 | |
| Pubmed | Molecular architecture of the multiprotein splicing factor SF3b. | 2.76e-05 | 3 | 106 | 2 | 12738865 | |
| Pubmed | 2.76e-05 | 3 | 106 | 2 | 32863381 | ||
| Pubmed | 2.76e-05 | 3 | 106 | 2 | 23376399 | ||
| Pubmed | 2.76e-05 | 3 | 106 | 2 | 24012335 | ||
| Pubmed | 2.76e-05 | 3 | 106 | 2 | 7737117 | ||
| Interaction | ITGB3 interactions | 2.22e-08 | 170 | 106 | 10 | int:ITGB3 | |
| Interaction | SUZ12 interactions | ZC3H14 SET MYO1E MCM2 TRRAP EFTUD2 BPTF NAA25 SF3B1 LATS2 SF3B6 PLEC IMMT VAV1 HDAC2 | 1.38e-06 | 644 | 106 | 15 | int:SUZ12 |
| Interaction | MDM2 interactions | TPT1 SET IPO7 UBE4B IREB2 CBL EFTUD2 LATS1 SF3B1 LATS2 SETD7 MTREX CDC25C UBE2Z HDAC2 | 1.80e-06 | 658 | 106 | 15 | int:MDM2 |
| Interaction | EED interactions | IPO5 TPT1 IPO7 MYO1E UBE4B MCM2 CBL TRRAP EFTUD2 BMI1 BPTF NAA25 UBA1 SF3B1 SF3B6 PLEC MTREX MGA IMMT UBE2Z VAV1 HDAC2 | 5.05e-06 | 1445 | 106 | 22 | int:EED |
| Interaction | CSNK2A2 interactions | IPO5 SET ESS2 ASH1L PTPN21 TRRAP TTLL7 EFTUD2 BMI1 LATS1 CCNB2 CDC25C MGA DYNC1LI2 HDAC2 | 5.22e-06 | 718 | 106 | 15 | int:CSNK2A2 |
| Interaction | KPNB1 interactions | IPO5 ZC3H14 IPO8 IPO7 RGPD1 RANBP6 MCM2 PHAX CCNB1 EFTUD2 BMI1 CDC25C HDAC2 | 5.63e-06 | 544 | 106 | 13 | int:KPNB1 |
| Interaction | UBE2D2 interactions | 6.94e-06 | 318 | 106 | 10 | int:UBE2D2 | |
| Interaction | SPICE1 interactions | 7.67e-06 | 191 | 106 | 8 | int:SPICE1 | |
| Interaction | H3-3A interactions | IPO5 SET ESS2 ASH1L MCM2 CHD9 PHAX TRRAP UBR7 BPTF SF3B1 CHD5 SETD7 MGA HDAC2 | 8.67e-06 | 749 | 106 | 15 | int:H3-3A |
| Interaction | KPNA1 interactions | 1.64e-05 | 351 | 106 | 10 | int:KPNA1 | |
| Interaction | H3-4 interactions | 2.42e-05 | 448 | 106 | 11 | int:H3-4 | |
| Interaction | SNW1 interactions | ATG5 ESS2 CCNB1 EFTUD2 BMI1 UBA1 SF3B1 VPS33B SF3B6 DIAPH1 PLEC MTREX DYNC1LI2 HDAC2 | 3.68e-05 | 747 | 106 | 14 | int:SNW1 |
| Interaction | RAN interactions | IPO5 IPO8 IPO7 ASH1L RGPD1 RANBP6 PHAX EFTUD2 SF3B6 IQCE HDAC2 | 4.12e-05 | 475 | 106 | 11 | int:RAN |
| Interaction | RECQL4 interactions | IPO5 SET IPO8 IPO7 APBA1 RANBP6 MCM2 MRPL45 PHAX TRRAP CCNB1 EFTUD2 UBA1 SF3B1 SETSIP PLEC MTREX IMMT MRPL1 HDAC2 | 4.13e-05 | 1412 | 106 | 20 | int:RECQL4 |
| Interaction | CYLD interactions | ATG5 IPO5 IPO8 RNF213 EFTUD2 SF3B1 LATS2 VPS33B SF3B6 PLEC SKA3 MTREX MGA ACAP2 MRPL1 | 4.82e-05 | 868 | 106 | 15 | int:CYLD |
| Interaction | YAP1 interactions | IPO5 ZC3H14 ESS2 IPO7 THUMPD1 PTPN21 PHAX TRRAP BPTF UBA1 LATS1 LATS2 PLEC SKA3 MGA IMMT HDAC2 | 5.54e-05 | 1095 | 106 | 17 | int:YAP1 |
| Interaction | MAD2L1 interactions | 5.61e-05 | 252 | 106 | 8 | int:MAD2L1 | |
| Interaction | H3C3 interactions | 5.97e-05 | 495 | 106 | 11 | int:H3C3 | |
| Interaction | CDK2 interactions | TPT1 SET IPO7 MCM2 CCNB1 EFTUD2 BMI1 NAA25 UBA1 LATS1 LATS2 CCNB2 PLEC CDC25C | 6.12e-05 | 783 | 106 | 14 | int:CDK2 |
| Interaction | IRF1 interactions | 7.67e-05 | 83 | 106 | 5 | int:IRF1 | |
| Interaction | PLK1 interactions | TPT1 TUT7 MCM2 CBL TRRAP TBC1D9 CCNB1 LATS1 SKA3 CDC25C HDAC2 | 7.80e-05 | 510 | 106 | 11 | int:PLK1 |
| Interaction | HSF1 interactions | IPO5 TPT1 ZC3H14 IPO8 IPO7 MCM2 TRRAP EFTUD2 SF3B1 MGA IMMT HDAC2 | 8.61e-05 | 609 | 106 | 12 | int:HSF1 |
| Interaction | KPNA2 interactions | IPO7 MCM2 RBM48 PHAX TRRAP EFTUD2 BMI1 UBA1 SF3B1 IMMT HDAC2 | 9.11e-05 | 519 | 106 | 11 | int:KPNA2 |
| Interaction | C9orf78 interactions | IPO5 IPO7 UBR7 CCNB1 EFTUD2 VPS33B DIAPH1 SETD7 MTREX IMMT DYNC1LI2 HDAC2 | 1.02e-04 | 620 | 106 | 12 | int:C9orf78 |
| Interaction | XRCC6 interactions | TPT1 SET MCM2 PHAX CBL TRRAP RYK CCNB1 EFTUD2 BPTF UBA1 SF3B1 DIAPH1 MGA VAV1 | 1.02e-04 | 928 | 106 | 15 | int:XRCC6 |
| Interaction | NCBP1 interactions | 1.03e-04 | 353 | 106 | 9 | int:NCBP1 | |
| Interaction | BAG2 interactions | ESS2 MCM2 CBL EFTUD2 BMI1 BPTF LATS2 CHD5 C1orf52 IRF2BPL SKA3 PPIP5K2 | 1.05e-04 | 622 | 106 | 12 | int:BAG2 |
| Interaction | SF3B5 interactions | 1.09e-04 | 143 | 106 | 6 | int:SF3B5 | |
| Interaction | H2AC14 interactions | 1.14e-04 | 144 | 106 | 6 | int:H2AC14 | |
| Interaction | OTUB1 interactions | 1.15e-04 | 358 | 106 | 9 | int:OTUB1 | |
| Interaction | THRAP3 interactions | 1.16e-04 | 443 | 106 | 10 | int:THRAP3 | |
| Interaction | UBE2L3 interactions | 1.27e-04 | 211 | 106 | 7 | int:UBE2L3 | |
| Interaction | OGT interactions | ATG5 IPO5 ESS2 THUMPD1 PHAX UBR7 CCNB1 EFTUD2 BMI1 UBA1 LATS1 SETD7 DYNC1LI2 TBCEL HDAC2 | 1.32e-04 | 950 | 106 | 15 | int:OGT |
| Interaction | FBL interactions | IPO5 SET IPO8 IPO7 TUT7 RANBP6 MCM2 PHAX TRRAP EFTUD2 BMI1 LATS1 | 1.35e-04 | 639 | 106 | 12 | int:FBL |
| Interaction | MRPL35 interactions | 1.39e-04 | 94 | 106 | 5 | int:MRPL35 | |
| Interaction | CBX3 interactions | SET ESS2 MYO1E MCM2 CHD9 EFTUD2 BMI1 CHD5 DIAPH1 C1orf52 MGA HDAC2 | 1.50e-04 | 646 | 106 | 12 | int:CBX3 |
| Interaction | CDC5L interactions | IPO5 ESS2 IPO7 DOCK8 XPA CCNB1 EFTUD2 SF3B1 VPS33B SF3B6 DIAPH1 PLEC MTREX DYNC1LI2 | 1.55e-04 | 855 | 106 | 14 | int:CDC5L |
| Interaction | ARHGEF7 interactions | 1.59e-04 | 153 | 106 | 6 | int:ARHGEF7 | |
| Interaction | CDKN1A interactions | 1.63e-04 | 375 | 106 | 9 | int:CDKN1A | |
| Interaction | MCMBP interactions | 1.82e-04 | 157 | 106 | 6 | int:MCMBP | |
| Interaction | YWHAH interactions | ZC3H14 MYO1E MCM2 PTPN21 CBL DNAH7 TTLL7 EFTUD2 UBA1 LATS1 LATS2 PLEC SKA3 MTREX PPIP5K2 CDC25C | 2.03e-04 | 1102 | 106 | 16 | int:YWHAH |
| Interaction | PRPSAP2 interactions | 2.03e-04 | 102 | 106 | 5 | int:PRPSAP2 | |
| Interaction | DDX39B interactions | ZC3H14 IPO7 MYO1E PHAX EFTUD2 BMI1 SF3B1 VPS33B PLEC IMMT DYNC1LI2 | 2.06e-04 | 570 | 106 | 11 | int:DDX39B |
| Interaction | TNPO1 interactions | 2.14e-04 | 306 | 106 | 8 | int:TNPO1 | |
| Interaction | GRWD1 interactions | 2.18e-04 | 390 | 106 | 9 | int:GRWD1 | |
| Interaction | SIAH2 interactions | 2.23e-04 | 104 | 106 | 5 | int:SIAH2 | |
| Interaction | OBSL1 interactions | ZC3H14 PCLO TUT7 MCM2 PTPN21 TRRAP EFTUD2 UBA1 SF3B1 PLEC MTREX MGA IMMT HDAC2 | 2.69e-04 | 902 | 106 | 14 | int:OBSL1 |
| Interaction | REPIN1 interactions | 2.77e-04 | 109 | 106 | 5 | int:REPIN1 | |
| Interaction | PHF5A interactions | 2.89e-04 | 171 | 106 | 6 | int:PHF5A | |
| Interaction | PRKDC interactions | TPT1 MCM2 XPA RYK CCNB1 EFTUD2 BMI1 SF3B1 LATS2 SF3B6 DIAPH1 HDAC2 | 2.93e-04 | 695 | 106 | 12 | int:PRKDC |
| Interaction | SETSIP interactions | 2.99e-04 | 25 | 106 | 3 | int:SETSIP | |
| Interaction | DHX15 interactions | 3.16e-04 | 502 | 106 | 10 | int:DHX15 | |
| Interaction | QARS1 interactions | 3.27e-04 | 412 | 106 | 9 | int:QARS1 | |
| Interaction | SIGLECL1 interactions | 3.28e-04 | 113 | 106 | 5 | int:SIGLECL1 | |
| Interaction | HSPB1 interactions | ATG5 TPT1 IPO7 MCM2 RBM48 CBL TRRAP EFTUD2 LATS1 ACAP2 IMMT VAV1 | 3.46e-04 | 708 | 106 | 12 | int:HSPB1 |
| Interaction | EP300 interactions | IPO5 SET IPO7 MCM2 XPA PHAX CBL CCNB1 BMI1 SF3B1 PIAS3 SETSIP SF3B6 MTREX SEC63 CDC25C IMMT HDAC2 | 3.54e-04 | 1401 | 106 | 18 | int:EP300 |
| Interaction | HSPA4L interactions | 3.57e-04 | 250 | 106 | 7 | int:HSPA4L | |
| Interaction | CCNB2 interactions | 3.60e-04 | 64 | 106 | 4 | int:CCNB2 | |
| Interaction | PTEN interactions | IPO5 SET IPO7 MCM2 CBL RYR3 EFTUD2 BMI1 UBA1 LATS1 SF3B1 PLEC ACAP2 EPHB1 | 3.62e-04 | 929 | 106 | 14 | int:PTEN |
| Interaction | ATG16L1 interactions | ATG5 IPO5 ZC3H14 IPO8 IPO7 TUT7 RANBP6 UBA1 VPS33B SF3B6 SETD7 PLEC MTREX IMMT VAV1 HDAC2 | 3.64e-04 | 1161 | 106 | 16 | int:ATG16L1 |
| Interaction | USP9X interactions | 3.89e-04 | 422 | 106 | 9 | int:USP9X | |
| Interaction | EFNB1 interactions | 4.02e-04 | 255 | 106 | 7 | int:EFNB1 | |
| Interaction | RBM6 interactions | 4.16e-04 | 119 | 106 | 5 | int:RBM6 | |
| Interaction | WWC2 interactions | 4.21e-04 | 28 | 106 | 3 | int:WWC2 | |
| Interaction | RPGRIP1 interactions | 4.30e-04 | 67 | 106 | 4 | int:RPGRIP1 | |
| Interaction | SRSF3 interactions | 4.30e-04 | 522 | 106 | 10 | int:SRSF3 | |
| Interaction | CALM1 interactions | 4.58e-04 | 626 | 106 | 11 | int:CALM1 | |
| Interaction | TIMM50 interactions | 4.62e-04 | 261 | 106 | 7 | int:TIMM50 | |
| Interaction | CSNK2A1 interactions | SET MCM2 PTPN21 TRRAP F5 TTLL7 EFTUD2 BMI1 SF3B1 SETSIP MTREX CDC25C MGA HDAC2 | 4.82e-04 | 956 | 106 | 14 | int:CSNK2A1 |
| Interaction | CUL7 interactions | IPO5 ZC3H14 TUT7 EFTUD2 BPTF UBA1 SF3B1 LATS2 SF3B6 PLEC MTREX IMMT HDAC2 | 4.90e-04 | 845 | 106 | 13 | int:CUL7 |
| Interaction | LIMD1 interactions | 5.02e-04 | 124 | 106 | 5 | int:LIMD1 | |
| Cytoband | 6q21 | 7.57e-05 | 96 | 106 | 4 | 6q21 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr6q21 | 1.85e-04 | 121 | 106 | 4 | chr6q21 | |
| Cytoband | 4q28 | 1.88e-04 | 9 | 106 | 2 | 4q28 | |
| Cytoband | 14q31.3 | 4.05e-04 | 13 | 106 | 2 | 14q31.3 | |
| Cytoband | 5q31 | 2.45e-03 | 115 | 106 | 3 | 5q31 | |
| GeneFamily | Armadillo repeat containing|Importins | 3.65e-05 | 18 | 66 | 3 | 596 | |
| GeneFamily | EF-hand domain containing | 1.46e-04 | 219 | 66 | 6 | 863 | |
| GeneFamily | PHD finger proteins|NuRD complex | 8.46e-04 | 12 | 66 | 2 | 1305 | |
| GeneFamily | Dyneins, axonemal | 1.72e-03 | 17 | 66 | 2 | 536 | |
| Coexpression | ZERBINI_RESPONSE_TO_SULINDAC_DN | 1.24e-06 | 6 | 105 | 3 | M17956 | |
| Coexpression | GABRIELY_MIR21_TARGETS | 2.53e-06 | 289 | 105 | 9 | M2196 | |
| Coexpression | GSE17721_CTRL_VS_GARDIQUIMOD_0.5H_BMDC_UP | 1.64e-05 | 200 | 105 | 7 | M3774 | |
| Coexpression | DAZARD_UV_RESPONSE_CLUSTER_G6 | 2.65e-05 | 145 | 105 | 6 | M1810 | |
| Coexpression | DAZARD_RESPONSE_TO_UV_NHEK_DN | 2.86e-05 | 300 | 105 | 8 | M8702 | |
| Coexpression | WHITFIELD_CELL_CYCLE_LITERATURE | 2.92e-05 | 44 | 105 | 4 | M2066 | |
| Coexpression | CUI_TCF21_TARGETS_2_DN | MYO1E TUT7 ASH1L CBL TTLL7 BMI1 LATS2 SCN7A SETD7 PPIP5K2 ACAP2 DYNC1LI2 EPHB1 | 3.75e-05 | 854 | 105 | 13 | M1533 |
| Coexpression | SIMBULAN_PARP1_TARGETS_DN | 4.08e-05 | 17 | 105 | 3 | M1642 | |
| Coexpression | CUI_TCF21_TARGETS_2_DN | MYO1E TUT7 ASH1L CBL TTLL7 BMI1 LATS2 SCN7A SETD7 PPIP5K2 ACAP2 DYNC1LI2 EPHB1 | 5.58e-05 | 888 | 105 | 13 | MM1018 |
| Coexpression | HAMAI_APOPTOSIS_VIA_TRAIL_UP | IPO5 TUT7 REV3L PHAX TBC1D9 TTLL7 BPTF MTREX PPIP5K2 SEC63 HDAC2 | 6.57e-05 | 656 | 105 | 11 | M18979 |
| Coexpression | GSE32901_NAIVE_VS_TH17_ENRICHED_CD4_TCELL_DN | 8.58e-05 | 179 | 105 | 6 | M8928 | |
| Coexpression | LAZARO_GENETIC_MOUSE_MODEL_HIGH_GRADE_SMALL_CELL_NEUROENDOCRINE_LUNG_CARCINOMA_UP | IPO5 MCM2 NBEA REV3L UBR7 CCNB1 CCNB2 ALDH1L2 SKA3 PPIP5K2 CDC25C | 9.04e-05 | 680 | 105 | 11 | MM456 |
| Coexpression | GSE7218_IGM_VS_IGG_SIGNAL_THGOUGH_ANTIGEN_BCELL_UP | 1.09e-04 | 187 | 105 | 6 | M6807 | |
| Coexpression | GSE28726_NAIVE_VS_ACTIVATED_CD4_TCELL_DN | 1.53e-04 | 199 | 105 | 6 | M8314 | |
| Coexpression | GSE26156_DOUBLE_POSITIVE_VS_CD4_SINGLE_POSITIVE_THYMOCYTE_DN | 1.53e-04 | 199 | 105 | 6 | M8299 | |
| Coexpression | GSE22527_ANTI_CD3_INVIVO_VS_UNTREATED_MOUSE_TREG_DN | 1.57e-04 | 200 | 105 | 6 | M7709 | |
| Coexpression | GSE13484_UNSTIM_VS_YF17D_VACCINE_STIM_PBMC_UP | 1.57e-04 | 200 | 105 | 6 | M3277 | |
| Coexpression | GSE36476_CTRL_VS_TSST_ACT_40H_MEMORY_CD4_TCELL_YOUNG_DN | 1.57e-04 | 200 | 105 | 6 | M5292 | |
| Coexpression | GSE23505_UNTREATED_VS_4DAY_IL6_IL1_TGFB_TREATED_CD4_TCELL_DN | 1.57e-04 | 200 | 105 | 6 | M7868 | |
| Coexpression | GSE43863_TH1_VS_TFH_EFFECTOR_CD4_TCELL_DN | 1.57e-04 | 200 | 105 | 6 | M9763 | |
| Coexpression | GSE557_CIITA_KO_VS_I_AB_KO_DC_DN | 1.57e-04 | 200 | 105 | 6 | M6014 | |
| Coexpression | GSE7831_CPG_VS_INFLUENZA_STIM_PDC_1H_UP | 1.57e-04 | 200 | 105 | 6 | M6950 | |
| Coexpression | CROONQUIST_NRAS_SIGNALING_DN | 1.82e-04 | 70 | 105 | 4 | M10739 | |
| Coexpression | MUELLER_PLURINET | 2.05e-04 | 299 | 105 | 7 | M123 | |
| ToppCell | 390C-Lymphocytic-CD4_T-cell-Proliferating_T_cell|390C / Donor, Lineage, Cell class and subclass (all cells) | 2.26e-06 | 159 | 106 | 6 | 0fbfdb18b7ed4bde077add13f2b3636e144b254f | |
| ToppCell | TCGA-Uterus-Primary_Tumor-Uterine_Carcinoma-Uterine_Carcinosarcoma-3|TCGA-Uterus / Sample_Type by Project: Shred V9 | 2.61e-06 | 163 | 106 | 6 | d64dd39b077105c73e570ccef70f0e74a2c586ac | |
| ToppCell | Healthy/Control-Plasmablast|Healthy/Control / Disease group and Cell class | 3.80e-06 | 174 | 106 | 6 | 97d19ef3240a1f648c6befaabb9ce45ad469cbce | |
| ToppCell | systemic_lupus_erythematosus-managed-Lymphocytic_B-plasmablast-male|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 3.93e-06 | 175 | 106 | 6 | 89bf89466191da14896ed8928027f5b911436c22 | |
| ToppCell | mild_COVID-19_(asymptomatic)-T/NK_proliferative|World / disease group, cell group and cell class (v2) | 4.92e-06 | 182 | 106 | 6 | 9adf90bb2808f234d53b89ca0ae07380478204ad | |
| ToppCell | mild_COVID-19_(asymptomatic)-T/NK_proliferative|mild_COVID-19_(asymptomatic) / disease group, cell group and cell class (v2) | 5.08e-06 | 183 | 106 | 6 | df8568751205313d149939ea2683097e3652a60b | |
| ToppCell | P07-Endothelial-proliferative_endothelial_cell|P07 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 6.89e-06 | 193 | 106 | 6 | 1e95ef29357969ee385b4717c0b5a497390ac260 | |
| ToppCell | P07-Endothelial-proliferative_endothelial_cell-proliferative_endothelial_cell|P07 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 6.89e-06 | 193 | 106 | 6 | 0f21fb8b35f89f4c1c8109d1a4d3d08a452f9edd | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22-Lymphocytic-Lymphocytic_B-Plasma_cell-B_c06-MKI67|Severe-critical_progression_d12-22 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 7.09e-06 | 194 | 106 | 6 | 5771a28a61f4d9b5479891f3224909ab003cb241 | |
| ToppCell | PBMC-Mild-Lymphocyte-B-Plasmablast-Plasmablast-Developping_Plasmablast|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 7.09e-06 | 194 | 106 | 6 | 5a519538327029ad2b880ef9647e2ac6ab3961a4 | |
| ToppCell | droplet-Lung-1m-Hematologic-myeloid-alveolar_macrophage-proliferating_alveolar_macrophage|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 7.30e-06 | 195 | 106 | 6 | c1435e61e4f0cf457f26ae436936048932ceb0db | |
| ToppCell | droplet-Pancreas-PANCREAS-30m-Epithelial-pancreatic_B_cell|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.30e-06 | 195 | 106 | 6 | 3e519cffa6144a62b06124642a14c9ff39b76554 | |
| ToppCell | droplet-Pancreas-PANCREAS-30m-Epithelial-pancreatic_B_cell|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.30e-06 | 195 | 106 | 6 | 7796ea9247f4c63762f0de8490fed08b9717fa23 | |
| ToppCell | Smart-start-Cell-Wel_seq-Neoplastic-Stem-like-OPC-like-OPC-like-G|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 7.52e-06 | 196 | 106 | 6 | 8faac7fbdee3a9297023c3151ef1751605413e44 | |
| ToppCell | MS-cycling-|MS / Condition, Cell_class and T cell subcluster | 7.97e-06 | 198 | 106 | 6 | 19c5d6b65de490118574b1f86b45c58b3a51df7f | |
| ToppCell | LPS_only-Epithelial_airway-airway_epithelial-Ciliated|LPS_only / Treatment groups by lineage, cell group, cell type | 7.97e-06 | 198 | 106 | 6 | 6d90b541fde357fbb40f8f7d4e8628a48b679718 | |
| ToppCell | MS-cycling|MS / Condition, Cell_class and T cell subcluster | 7.97e-06 | 198 | 106 | 6 | 0c22f2cc0e5ca91cabcd4aac2b9ef05af47e967f | |
| ToppCell | 10x_3'_v2v3-Neoplastic-Stem-like-OPC-like-OPC-like_Prolif-F|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 7.97e-06 | 198 | 106 | 6 | cd876fba12ff30b74aa507286cb1f3a867011a92 | |
| ToppCell | 3'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2_proliferating-AT2_proliferating_L.0.1.2.2|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 8.20e-06 | 199 | 106 | 6 | d7dbc551c05da32c698908348572fb0ce1166e10 | |
| ToppCell | proximal-Epithelial-Proliferating_Basal|proximal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 8.20e-06 | 199 | 106 | 6 | 521ff4ae3437c8ba477a0a42b9da195af976c3ff | |
| ToppCell | 5'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2_proliferating|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 8.20e-06 | 199 | 106 | 6 | f0944961f99c600ad5fa588b19321fce991258f7 | |
| ToppCell | 3'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2_proliferating|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 8.20e-06 | 199 | 106 | 6 | 6a89c3a65fa50af92585c52bec203bcff6f94efc | |
| ToppCell | proximal-Epithelial-Proliferating_Basal-3|proximal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 8.20e-06 | 199 | 106 | 6 | e8549b2c4152cb23548351d9cee27c3805892cd8 | |
| ToppCell | 5'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2_proliferating-AT2_proliferating_L.0.1.2.2|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 8.20e-06 | 199 | 106 | 6 | 99437f8b57d168c550ccfd1fbda5454c26f971a8 | |
| ToppCell | Neuron-Postmitotic-Excitatory_Neuron_-Parietal_and_Temporal-6|World / Primary Cells by Cluster | 8.20e-06 | 199 | 106 | 6 | 1b1bccf4293f11048709d15a3c892c0edf3da3d2 | |
| ToppCell | proximal-3-Epithelial-Proliferating_Basal|3 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 8.20e-06 | 199 | 106 | 6 | 2263bb73d9c5693b44d91d2548305efc1b6e4079 | |
| ToppCell | Neuron-Postmitotic-Excitatory_Neuron_-Parietal_and_Temporal|World / Primary Cells by Cluster | 8.20e-06 | 199 | 106 | 6 | 4bee94c116c0da5eba951cb4cea7cc9dcdd6e30f | |
| ToppCell | Sepsis-URO-Lymphocyte-B-Plasmablast|URO / Disease, condition lineage and cell class | 8.20e-06 | 199 | 106 | 6 | 0df6cafb7f3b607cbe80b6f25b4fd62d421d01ee | |
| ToppCell | LPS-IL1RA+antiTNF-Epithelial_airway-Ciliated_cells|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.48e-05 | 155 | 106 | 5 | 5f1e2195a6b831e1b636f5cc3a282ca423721822 | |
| ToppCell | LPS-IL1RA+antiTNF-Epithelial_airway-Ciliated_cells-Ciliated|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.48e-05 | 155 | 106 | 5 | 0944429459f642a1bcc56edc1ec28aaecde3e2dc | |
| ToppCell | 343B-Lymphocytic-Plasma_cell|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 4.56e-05 | 164 | 106 | 5 | cf62d34ce9dd220fe61748466c84fd70d9ba697c | |
| ToppCell | 343B-Lymphocytic-Plasma_cell-|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 4.56e-05 | 164 | 106 | 5 | e00549bc8b3a5566f39031f39d7e698b0b107a7f | |
| ToppCell | 3'-Airway_Nasal-Epithelial-Airway_epithelium-brush_cell_of_trachebronchial_tree-Tuft|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.69e-05 | 165 | 106 | 5 | 0ae39c9a6d1265d65dc0660924612cfe11e489ec | |
| ToppCell | 3'-Airway_Nasal-Epithelial-Airway_epithelium-brush_cell_of_trachebronchial_tree-Tuft-Tuft_L.0.7.1.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.69e-05 | 165 | 106 | 5 | 686cf89077cc7b744a6127de2b34d8c27da8b6c4 | |
| ToppCell | 3'-Airway_Nasal-Epithelial-Airway_epithelium-brush_cell_of_trachebronchial_tree|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.69e-05 | 165 | 106 | 5 | a5ed8c331d5551cd8bce50bdc31cb893218317cd | |
| ToppCell | droplet-Lung-3m-Hematologic-myeloid-classical_monocyte-classical_monocyte_l2-17-52|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 4.83e-05 | 166 | 106 | 5 | de319c960b0cd90b294f677d1ea1b013a2ce2d53 | |
| ToppCell | renal_medulla_nuclei-Adult_normal_reference-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 5.11e-05 | 168 | 106 | 5 | fc80e4fecfc92458eb627013a983041d8ca025a9 | |
| ToppCell | renal_medulla_nuclei-Adult_normal_reference-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell-Podocyte|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 5.11e-05 | 168 | 106 | 5 | e96859dbf51cf8c4def8ee8db132f4d874fb4381 | |
| ToppCell | facs-Diaphragm-Limb_Muscle-24m|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.26e-05 | 169 | 106 | 5 | 12bdc709bc000d7f9061ecd9fbd57233eaacb7e2 | |
| ToppCell | 390C-Lymphocytic-NK_cells-Proliferating_NK_cell|390C / Donor, Lineage, Cell class and subclass (all cells) | 5.41e-05 | 170 | 106 | 5 | 5319f73cff64f2bb67472c7156ee1d0f006c6fc0 | |
| ToppCell | 367C-Lymphocytic-NK_cells-Proliferating_NK_cell|367C / Donor, Lineage, Cell class and subclass (all cells) | 5.56e-05 | 171 | 106 | 5 | 4ede6e916e593f208f2f8ccf82ef2335e061fc86 | |
| ToppCell | Healthy/Control-Plasmablast|World / Disease group and Cell class | 5.71e-05 | 172 | 106 | 5 | d3bfcf5d936152b71cd90f955f9331709edd979e | |
| ToppCell | PND28-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_T-Treg-Treg_G2M|PND28 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 5.71e-05 | 172 | 106 | 5 | 1171e754fd503a0c1152162fcc12a115088a08c7 | |
| ToppCell | URO-Lymphocyte-B-Plasmablast|URO / Disease, Lineage and Cell Type | 5.71e-05 | 172 | 106 | 5 | 48888ef50ac784b38aca81da68f8a94ce09c670d | |
| ToppCell | facs-Diaphragm-Limb_Muscle-24m-Mesenchymal|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.87e-05 | 173 | 106 | 5 | 66f37c1437705734b20601656fa4aa1d92ca30be | |
| ToppCell | facs-Diaphragm-Limb_Muscle-24m-Mesenchymal-nan|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.87e-05 | 173 | 106 | 5 | 649b08a409095592cccf31883be69c754411280d | |
| ToppCell | PND14-Immune-Immune_Myeloid-DC-cDC1-cDC1_prolif|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 6.04e-05 | 174 | 106 | 5 | 09b091e24317c3f7bac043f04762a533e30793de | |
| ToppCell | Control-B_cells-Plasma_cells|Control / group, cell type (main and fine annotations) | 6.20e-05 | 175 | 106 | 5 | fb23858cfce71509cafbe0d9728e678012ff2962 | |
| ToppCell | 367C-Lymphocytic-NK_cells-Proliferating_NK_cell|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 6.20e-05 | 175 | 106 | 5 | 0b1aaa028ba844d4bcb4509fdab8bee648373935 | |
| ToppCell | 367C-Myeloid-Dendritic-cDC_proliferating_1|Myeloid / Donor, Lineage, Cell class and subclass (all cells) | 6.20e-05 | 175 | 106 | 5 | 6b4e841bde6cfa4956e1a0231672cea20f11210c | |
| ToppCell | Striatum-Macroglia-POLYDENDROCYTE-P5-P5_1-Sox4|Striatum / BrainAtlas - Mouse McCarroll V32 | 6.37e-05 | 176 | 106 | 5 | d70fdc7bc48719776ed1e7c01118385e3a21623f | |
| ToppCell | Striatum-Macroglia-POLYDENDROCYTE-P5-P5_1|Striatum / BrainAtlas - Mouse McCarroll V32 | 6.37e-05 | 176 | 106 | 5 | a84361308e5e96f3a30246cd29e109c321ee65bf | |
| ToppCell | 356C-Myeloid-Dendritic-cDC_proliferating_2|356C / Donor, Lineage, Cell class and subclass (all cells) | 6.37e-05 | 176 | 106 | 5 | 4bba41ebf9dd187c8705a6997ed039878de62b4e | |
| ToppCell | 367C-Myeloid-Dendritic-cDC_proliferating_1|367C / Donor, Lineage, Cell class and subclass (all cells) | 6.55e-05 | 177 | 106 | 5 | ba701d3c90722d8bff70d0fa651899305cdad257 | |
| ToppCell | facs-Brain_Non-Myeloid-Striatum-24m-Mesenchymal-ependymal_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.72e-05 | 178 | 106 | 5 | b1db59344c074c7c80169fc2c5cd5fc89f3fe463 | |
| ToppCell | facs-Brain_Non-Myeloid-Striatum-24m-Mesenchymal-Ependyma|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.72e-05 | 178 | 106 | 5 | 579cdc14f28b459e200ae2102e0bd4df8a2c0dcb | |
| ToppCell | droplet-Lung-30m-Hematologic-myeloid-classical_monocyte-classical_monocyte_l2-17-52|30m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 6.90e-05 | 179 | 106 | 5 | af03705a783e77f75c44fdfa793cfdccbf9dd91c | |
| ToppCell | TCGA-Adrenal-Primary_Tumor-Pheochromocytoma-Pheochromocytoma-1|TCGA-Adrenal / Sample_Type by Project: Shred V9 | 6.90e-05 | 179 | 106 | 5 | 431e1b29015ec817f778499106d24b19cfc825ae | |
| ToppCell | Control-Developping_Plasmablast|Control / disease group and sub_cluster of B and Plasma cells(res = 0.5) | 6.90e-05 | 179 | 106 | 5 | 9383568f78b07b8cca72ece5d15fea209aa54ea9 | |
| ToppCell | 3'-Parenchyma_lung-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.3.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 7.09e-05 | 180 | 106 | 5 | 92fb01b91261b3103454924cde56add337b41844 | |
| ToppCell | PND01-Endothelial-Endothelial_blood-vessel-Microvascular_EC-EPC|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 7.09e-05 | 180 | 106 | 5 | b35a8c6169f4b548b912af005e92ae7c6596f376 | |
| ToppCell | 368C-Lymphocytic-CD4_T-cell-Treg_cell_3|368C / Donor, Lineage, Cell class and subclass (all cells) | 7.27e-05 | 181 | 106 | 5 | b193f3606554adc55c5906219d114288bb1f978a | |
| ToppCell | P28-Endothelial-proliferative_endothelial_cell-proliferative_endothelial_cell|P28 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 7.27e-05 | 181 | 106 | 5 | e482fd116c00ff4d8db7be3c06b1bd1ffa2d479d | |
| ToppCell | P28-Endothelial-proliferative_endothelial_cell|P28 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 7.27e-05 | 181 | 106 | 5 | 2be3d44619adb25d339e7a27b500a56e07e8de01 | |
| ToppCell | facs-Skin-Skin_Anagen-18m-Epithelial-actively_dividing_stem_cell|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.47e-05 | 182 | 106 | 5 | bc6a120dedc813c58baac1428c39851a07b71ba7 | |
| ToppCell | droplet-Marrow-nan-3m-Myeloid-nan|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.47e-05 | 182 | 106 | 5 | f8c73baaaca145e2efc48f10f636feb79c8fc779 | |
| ToppCell | droplet-Heart-HEART-1m-Mesenchymal-nan|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.47e-05 | 182 | 106 | 5 | c84f44391932080df31c8765e363c3dff64b2bd1 | |
| ToppCell | facs-Skin-Skin_Anagen-18m-Epithelial-keratinocyte_stem_cell|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.47e-05 | 182 | 106 | 5 | 0fc45214f0b0766f69be6eff69cc4bec574023aa | |
| ToppCell | 10x5'-bone_marrow-Lymphocytic_T_CD4/8-lo-Cycling_T|bone_marrow / Manually curated celltypes from each tissue | 7.66e-05 | 183 | 106 | 5 | a48a6313f2f144586951cece97ec31f6d72361df | |
| ToppCell | 18-Airway-Epithelial-Multiciliated_precursor|Airway / Age, Tissue, Lineage and Cell class | 7.66e-05 | 183 | 106 | 5 | a75cda2131755931117c387f2e0ae3394efa8e80 | |
| ToppCell | droplet-Lung-18m-Hematologic-myeloid-alveolar_macrophage-proliferating_alveolar_macrophage|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 7.66e-05 | 183 | 106 | 5 | e91f00b75d43ee6293fdd4a129b789cd95f8d11a | |
| ToppCell | Striatum-Macroglia-POLYDENDROCYTE-P5|Striatum / BrainAtlas - Mouse McCarroll V32 | 7.66e-05 | 183 | 106 | 5 | f20b0d71f857ac35868fd80531050ad8b6091716 | |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.86e-05 | 184 | 106 | 5 | 2cbed6462fea2622871bb7e49b0df3d984239281 | |
| ToppCell | TCGA-Pancreas-Primary_Tumor-Pancreatic_Adenocarcinoma-Ductal_Adenocarcinoma-4|TCGA-Pancreas / Sample_Type by Project: Shred V9 | 7.86e-05 | 184 | 106 | 5 | 67164bb6bcae7322cb89b585c7aa10bce35b0ecd | |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.86e-05 | 184 | 106 | 5 | ea7a7e2bac46d4d2c31a5d576b38a032b5335062 | |
| ToppCell | Control-Neu_4|World / 5 Neutrophil clusters in COVID-19 patients | 7.86e-05 | 184 | 106 | 5 | ce7f044956613118ee2e9fb6af2455c3166cb414 | |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.86e-05 | 184 | 106 | 5 | 2b19a8c5f823e00812908b23e66bb4e563278aff | |
| ToppCell | COVID-cycling-|COVID / Condition, Cell_class and T cell subcluster | 8.06e-05 | 185 | 106 | 5 | eb74b8d36f7b749e04bc2ed4b36f7e1ac7bb6d5f | |
| ToppCell | COVID-cycling|COVID / Condition, Cell_class and T cell subcluster | 8.06e-05 | 185 | 106 | 5 | 5112f966735fa48f0606adcfd5c0212ad5d3d77a | |
| ToppCell | mild_COVID-19-Plasmablast|mild_COVID-19 / disease group, cell group and cell class (v2) | 8.27e-05 | 186 | 106 | 5 | a639d2183b85b1be6e6da2b2e112aec5149d5bcd | |
| ToppCell | 10x5'-lymph-node_spleen-Hematopoietic_Erythro-Mega-Erythrocytic_early|lymph-node_spleen / Manually curated celltypes from each tissue | 8.48e-05 | 187 | 106 | 5 | 61d346c9873c2edb3ce224a0c063c54d9a68309e | |
| ToppCell | severe_COVID-19-Plasmablast|World / disease group, cell group and cell class (v2) | 8.70e-05 | 188 | 106 | 5 | 25ca19af4ac419a0f5026a6ccbd8b554b268a6f3 | |
| ToppCell | Multiple_Sclerosis-Lymphocyte-T_NK-T_NK_proliferative|Multiple_Sclerosis / Disease, Lineage and Cell Type | 8.70e-05 | 188 | 106 | 5 | 6c05797a5d0635d89ffcf4aca52178687129ccb4 | |
| ToppCell | normal-na-Lymphocytic|normal / PBMC cell types (v2) per disease, treatment status, and sex | 8.92e-05 | 189 | 106 | 5 | 1d382f8eb998c6a30e09fddc9a427afc8f5f7323 | |
| ToppCell | normal-na-Lymphocytic-lymphocyte|normal / PBMC cell types (v2) per disease, treatment status, and sex | 8.92e-05 | 189 | 106 | 5 | b83fd81ecc5ef363be7435ee12cb7079e2434af7 | |
| ToppCell | 5'-Airway_Nasal-Epithelial-Airway_ciliated-multi-ciliated_epithelial_cell-Multiciliated_(nasal)|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 8.92e-05 | 189 | 106 | 5 | b4b93bd10b7e3cc16e54ff73beac230f519c010a | |
| ToppCell | normal-na-Lymphocytic-lymphocyte-female|normal / PBMC cell types (v2) per disease, treatment status, and sex | 8.92e-05 | 189 | 106 | 5 | 3db4177d68cab4cd16842d2ebcaca28f69300e44 | |
| ToppCell | Int-URO-Lymphocyte-T_NK-T_NK_proliferative|Int-URO / Disease, Lineage and Cell Type | 9.14e-05 | 190 | 106 | 5 | 005967c540418b85311308072a07c684f4296aef | |
| ToppCell | droplet-Spleen-nan-18m-Lymphocytic-immature_NKT_cell|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.14e-05 | 190 | 106 | 5 | b99271d139c8d01e20feb95d99f79c9b2756b4cb | |
| ToppCell | droplet-Lung-21m-Hematologic-lymphocytic-Proliferating_T_cell-proliferating_T|21m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 9.37e-05 | 191 | 106 | 5 | 15dbc5a03bfab8931c0fd385b0f25874736ae874 | |
| ToppCell | facs-Trachea-nan-3m-Lymphocytic|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.37e-05 | 191 | 106 | 5 | 89eb4e30052d0d4a2952157ca743291900ce8de2 | |
| ToppCell | facs-Trachea-nan-3m-Lymphocytic-T_cell|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.37e-05 | 191 | 106 | 5 | 0bf575eba311745fb75f9523f7fc81f73848e25d | |
| ToppCell | droplet-Lung-21m-Hematologic-lymphocytic-Proliferating_T_cell|21m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 9.37e-05 | 191 | 106 | 5 | 45c15f5ce4a207ac944bed65d45f06c1657d1a6d | |
| ToppCell | facs-Trachea-nan-3m-Lymphocytic-nan|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.37e-05 | 191 | 106 | 5 | c57df363e3a6e61d2bdca1955330f1899b964267 | |
| ToppCell | systemic_lupus_erythematosus-managed-Lymphocytic-lymphocyte-male|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 9.37e-05 | 191 | 106 | 5 | 56b45259dfc38bd5ea43b0e3adf47e7e2c043a5d | |
| ToppCell | droplet-Tongue-Unstain-18m-Epithelial|Tongue / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.60e-05 | 192 | 106 | 5 | 45ff9555f9a9fccc650885956005b2e5b4820a56 | |
| ToppCell | droplet-Tongue-Unstain|Tongue / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.60e-05 | 192 | 106 | 5 | 0f0fae7e1177609eff82fa4452042306297a7103 | |
| ToppCell | droplet-Tongue-Unstain-18m|Tongue / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.60e-05 | 192 | 106 | 5 | b198e42a962c4e24ea9faad867ca1255316a5d99 | |
| ToppCell | normal_Lymph_Node-B_lymphocytes-GC_B_cells_in_the_DZ|normal_Lymph_Node / Location, Cell class and cell subclass | 9.84e-05 | 193 | 106 | 5 | 5ce93860bc60ce6ecfed3a3d985f84e28781eec1 | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c14-MKI67-CCL5_h|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 9.84e-05 | 193 | 106 | 5 | cf680afddc08b6481f1b3eee9c57acfaebeac6f0 | |
| Computational | Genes in the cancer module 57. | 4.75e-05 | 56 | 77 | 5 | MODULE_57 | |
| Computational | Neighborhood of PRKDC | 6.33e-05 | 191 | 77 | 8 | MORF_PRKDC | |
| Computational | Neighborhood of RFC4 | 9.92e-05 | 151 | 77 | 7 | MORF_RFC4 | |
| Computational | Neighborhood of RAD54L | 1.02e-04 | 105 | 77 | 6 | MORF_RAD54L | |
| Computational | Neighborhood of BUB1B | 1.05e-04 | 66 | 77 | 5 | MORF_BUB1B | |
| Computational | Neighborhood of PPP1CC | 1.79e-04 | 166 | 77 | 7 | MORF_PPP1CC | |
| Computational | Neighborhood of MLL | 2.39e-04 | 174 | 77 | 7 | GCM_MLL | |
| Computational | Neighborhood of BUB1 | 5.08e-04 | 52 | 77 | 4 | MORF_BUB1 | |
| Computational | Neighborhood of MSH2 | 9.32e-04 | 61 | 77 | 4 | MORF_MSH2 | |
| Computational | Neighborhood of PAK2 | 1.02e-03 | 28 | 77 | 3 | GNF2_PAK2 | |
| Drug | irinotecan HCl; Down 200; 100uM; MCF7; HT_HG-U133A | 1.93e-07 | 183 | 106 | 9 | 7498_DN | |
| Drug | 1m0o | 6.29e-06 | 56 | 106 | 5 | CID006323413 | |
| Disease | Intellectual Disability | 4.23e-06 | 447 | 104 | 10 | C3714756 | |
| Disease | hepatocellular carcinoma (is_implicated_in) | 4.52e-05 | 181 | 104 | 6 | DOID:684 (is_implicated_in) | |
| Disease | phospholipids in large VLDL measurement | 6.94e-05 | 62 | 104 | 4 | EFO_0022169 | |
| Disease | benign neoplasm (implicated_via_orthology) | 3.40e-04 | 8 | 104 | 2 | DOID:0060072 (implicated_via_orthology) | |
| Disease | Gastric Adenocarcinoma | 5.42e-04 | 45 | 104 | 3 | C0278701 | |
| Disease | kidney cancer (implicated_via_orthology) | 6.63e-04 | 11 | 104 | 2 | DOID:263 (implicated_via_orthology) | |
| Disease | Adenocarcinoma of lung (disorder) | 8.30e-04 | 206 | 104 | 5 | C0152013 | |
| Disease | platelet measurement | 8.92e-04 | 315 | 104 | 6 | EFO_0005036 | |
| Disease | triglycerides in medium VLDL measurement | 9.77e-04 | 55 | 104 | 3 | EFO_0022155 | |
| Disease | Squamous cell carcinoma | 9.88e-04 | 124 | 104 | 4 | C0007137 | |
| Disease | triglycerides in large VLDL measurement | 1.03e-03 | 56 | 104 | 3 | EFO_0022178 | |
| Disease | Autosomal recessive limb-girdle muscular dystrophy | 1.09e-03 | 14 | 104 | 2 | cv:C2931907 | |
| Disease | triglycerides in small VLDL measurement | 1.32e-03 | 61 | 104 | 3 | EFO_0022145 | |
| Disease | very low density lipoprotein cholesterol measurement, phospholipid measurement | 1.33e-03 | 229 | 104 | 5 | EFO_0004639, EFO_0008317 | |
| Disease | total lipids in very large VLDL measurement | 1.38e-03 | 62 | 104 | 3 | EFO_0022313 | |
| Disease | phospholipids in very large VLDL measurement | 1.38e-03 | 62 | 104 | 3 | EFO_0022299 | |
| Disease | endometriosis (biomarker_via_orthology) | 1.43e-03 | 16 | 104 | 2 | DOID:289 (biomarker_via_orthology) | |
| Disease | level of Phosphatidylethanolamine (16:0_20:4) in blood serum | 1.43e-03 | 16 | 104 | 2 | OBA_2045137 | |
| Disease | cholesterol in large VLDL measurement | 1.59e-03 | 65 | 104 | 3 | EFO_0021902 | |
| Disease | cholesterol in very large VLDL measurement | 1.59e-03 | 65 | 104 | 3 | EFO_0022230 | |
| Disease | rhinitis | 1.62e-03 | 17 | 104 | 2 | EFO_0008521 | |
| Disease | Ischemic stroke, venous thromboembolism, stroke, Abnormal thrombosis, deep vein thrombosis, pulmonary embolism | 1.62e-03 | 17 | 104 | 2 | EFO_0000712, EFO_0003827, EFO_0003907, EFO_0004286, HP_0001977, HP_0002140 | |
| Disease | Liver Cirrhosis, Experimental | 1.68e-03 | 774 | 104 | 9 | C0023893 | |
| Disease | total lipids in large VLDL | 1.73e-03 | 67 | 104 | 3 | EFO_0022175 | |
| Disease | MYELODYSPLASTIC SYNDROME | 1.73e-03 | 67 | 104 | 3 | C3463824 | |
| Disease | free cholesterol in large VLDL measurement | 1.81e-03 | 68 | 104 | 3 | EFO_0022265 | |
| Disease | visceral:subcutaneous adipose tissue ratio | 1.96e-03 | 70 | 104 | 3 | EFO_0004767 | |
| Disease | body mass index, high density lipoprotein cholesterol measurement | 2.02e-03 | 19 | 104 | 2 | EFO_0004340, EFO_0004612 | |
| Disease | type 1 diabetes mellitus (biomarker_via_orthology) | 2.02e-03 | 19 | 104 | 2 | DOID:9744 (biomarker_via_orthology) | |
| Disease | triglyceride measurement, body mass index | 2.02e-03 | 19 | 104 | 2 | EFO_0004340, EFO_0004530 | |
| Disease | triglyceride measurement, body fat percentage | 2.47e-03 | 21 | 104 | 2 | EFO_0004530, EFO_0007800 | |
| Disease | prothrombin time measurement | 2.47e-03 | 21 | 104 | 2 | EFO_0008390 | |
| Disease | venous thromboembolism, plasminogen activator inhibitor 1 measurement | 2.47e-03 | 21 | 104 | 2 | EFO_0004286, EFO_0004792 | |
| Disease | disease | 2.47e-03 | 21 | 104 | 2 | EFO_0000408 | |
| Disease | cancer (implicated_via_orthology) | 2.64e-03 | 268 | 104 | 5 | DOID:162 (implicated_via_orthology) | |
| Disease | Ovarian Serous Adenocarcinoma | 2.97e-03 | 23 | 104 | 2 | C1335177 | |
| Disease | venous thromboembolism, tissue plasminogen activator measurement | 2.97e-03 | 23 | 104 | 2 | EFO_0004286, EFO_0004791 | |
| Disease | cholesterol:total lipids ratio, high density lipoprotein cholesterol measurement | 2.99e-03 | 276 | 104 | 5 | EFO_0004612, EFO_0020943 | |
| Disease | partial thromboplastin time | 3.23e-03 | 24 | 104 | 2 | EFO_0004310 | |
| Disease | mean platelet volume | 3.24e-03 | 1020 | 104 | 10 | EFO_0004584 | |
| Disease | response to anticonvulsant | 3.41e-03 | 85 | 104 | 3 | GO_0036277 | |
| Disease | Cerebral Astrocytoma | 3.50e-03 | 25 | 104 | 2 | C0750935 | |
| Disease | Intracranial Astrocytoma | 3.50e-03 | 25 | 104 | 2 | C0750936 | |
| Disease | Astrocytoma | 3.50e-03 | 25 | 104 | 2 | C0004114 | |
| Disease | Grade I Astrocytoma | 3.50e-03 | 25 | 104 | 2 | C1704230 | |
| Disease | Subependymal Giant Cell Astrocytoma | 3.50e-03 | 25 | 104 | 2 | C0205768 | |
| Disease | Mixed oligoastrocytoma | 3.50e-03 | 25 | 104 | 2 | C0547065 | |
| Disease | Pilocytic Astrocytoma | 3.50e-03 | 25 | 104 | 2 | C0334583 | |
| Disease | Juvenile Pilocytic Astrocytoma | 3.50e-03 | 25 | 104 | 2 | C0280783 | |
| Disease | Diffuse Astrocytoma | 3.50e-03 | 25 | 104 | 2 | C0280785 | |
| Disease | Childhood Cerebral Astrocytoma | 3.50e-03 | 25 | 104 | 2 | C0338070 | |
| Disease | body fat percentage, high density lipoprotein cholesterol measurement | 3.50e-03 | 25 | 104 | 2 | EFO_0004612, EFO_0007800 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| ALKDMPAGTELTYDY | 2246 | Q9NR48 | |
| KMLDLLEDFLEYEGY | 1051 | Q8TDI0 | |
| GEVAEDMFGYFEPLY | 106 | Q8NC06 | |
| GVEKTGSDEPAFMYY | 301 | O14977 | |
| EDYMYLAKEESFGPI | 816 | Q3SY69 | |
| YEAMPDYLEDGKVNV | 366 | O95267 | |
| AFESGIPVDMKDNYY | 511 | Q9NU02 | |
| GYDLFSELGPYMKDL | 206 | Q15057 | |
| MAAEEKDPLSYFAAY | 1 | Q8N6N3 | |
| KLMEYPAEENGFRYI | 171 | Q9H1Y0 | |
| METLYKELGEYFLFD | 1111 | O60610 | |
| APDYYGVIKEPMDLA | 2961 | Q12830 | |
| EYFLEPIMKADGNEY | 161 | P59510 | |
| YPAEDFTEVYLIKFM | 81 | Q5RL73 | |
| GPYFLALREMIEEMY | 171 | Q8NCC3 | |
| MDAPKAGYAFEYLIE | 1 | P48200 | |
| GTPVYREKEDMYDEI | 136 | Q6IPM2 | |
| EAALEVVLAMYPKYD | 261 | P49736 | |
| MKIYIDPFTYEDPNE | 591 | P54762 | |
| REEDKDPVYLYFESM | 1221 | Q8IWI9 | |
| DNLYFVMDYIPGGDM | 776 | O95835 | |
| QDKDSLYFVMDYIPG | 736 | Q9NRM7 | |
| IDVMYEEEPLKDYYT | 191 | P35226 | |
| EEEPLKDYYTLMDIA | 196 | P35226 | |
| AKEPLINYLDMEYFG | 66 | P14091 | |
| KFVKDFQDYMEPEEG | 176 | O43237 | |
| EKADAIYDMIGFPDF | 536 | P0DPD6 | |
| MKDHYIFYCEGRDPE | 111 | Q5VSP4 | |
| MPYLERLDKEFYEEE | 296 | Q53EV4 | |
| PGMDYELKLFIEYPT | 411 | Q9H1B7 | |
| FEKEPLYGGMLIEDY | 1941 | Q9Y6V0 | |
| YVESFEKMGIYLAEP | 51 | Q9NYQ8 | |
| DPYEYIRMKFDVFED | 371 | O95373 | |
| MKPDRDTLDEYFEYD | 1 | Q32MH5 | |
| IVEYDYKPEFASAMG | 476 | Q96LU7 | |
| YSDKLFEMVLGPAAY | 81 | Q16891 | |
| DVEINGIFPDIYKMY | 326 | P22413 | |
| FEDDKELYPMIEEYF | 706 | Q07075 | |
| AVYEEMKYPIFDDLG | 266 | Q9P242 | |
| DTAEEKFVPYYDLFM | 521 | O00410 | |
| ILKGGYRDFFPEYME | 411 | P30307 | |
| VERMDGYGEESYPAK | 211 | Q16825 | |
| ADYAMFKVGPEADKY | 286 | P02679 | |
| KNSLMYYPEGVPDEE | 221 | Q96DF8 | |
| DYMDGDVEDPEYKPA | 1726 | Q3L8U1 | |
| SKYEEMYPPEIGDFA | 256 | P14635 | |
| FMLFKEGYAEPVDYQ | 161 | Q8N6C5 | |
| TFVEPYFDEYEMKDR | 1866 | Q8NF50 | |
| DKDGLVTPEEFMNYY | 171 | Q8WWF8 | |
| KYEEMFSPNIEDFVY | 221 | O95067 | |
| DYAASLPEDDVDYKM | 181 | O75460 | |
| DLLGFDYEVMEDKEY | 3901 | Q8WXX0 | |
| KEAEFAPYPRMDSYE | 251 | Q02410 | |
| LFKTGDYPAAMREYI | 776 | Q86Z14 | |
| PGYMAFLTYDEVKAR | 266 | P22681 | |
| KYYAVNFPMRDGIDD | 221 | Q92769 | |
| FEKYVPYLMDVIVEG | 2281 | Q8IVF4 | |
| IDPFEMAAYLKDGYR | 546 | P34925 | |
| PEDKVAFEFVLEYMD | 136 | Q8IZU8 | |
| PEMNYKGRYEITAED | 211 | Q9H814 | |
| MQELEDYSEGGPLYK | 741 | P0DJD0 | |
| ISNKEPLDFEEYKMY | 301 | Q9Y5H4 | |
| EDPYEYIRMKFDIFE | 371 | O15397 | |
| YEEMKYPLPEEAGEG | 261 | Q6ZVC0 | |
| EKMDDAVAPGREYTY | 136 | P12259 | |
| LMYGQEDVPKDVLEY | 231 | Q9BRJ2 | |
| FIDGYYEEPMDVVAL | 336 | Q8WZA1 | |
| VKELIPEFYYLPEMF | 2431 | Q8NFP9 | |
| QYYLVPDMDDEEGGE | 241 | P0DME0 | |
| DGEMTGEKIAYVYPD | 136 | Q8WTS6 | |
| QYYLVPDMDDEEGEG | 231 | Q01105 | |
| IEEKFVPYYDIFMPS | 531 | O60518 | |
| FLYYEDMKENPKEEI | 191 | O43704 | |
| DVTMKPLPFYEVYGE | 126 | Q9Y6X2 | |
| GEESDFEDYPMRILY | 31 | Q8IX90 | |
| PGQMDRYLVYGDEYK | 4321 | Q63HN8 | |
| PYMEGEPEDDVYLKR | 76 | Q9BYD6 | |
| VEEINPEYMLEKSFY | 576 | P42285 | |
| VGYMYETLDQKDPVF | 2836 | O60673 | |
| DPAGDPYEMYRIVFD | 4736 | Q15413 | |
| MGKDYIYAVTPLLED | 1161 | O75533 | |
| LPYKITAEEMYDIFG | 26 | Q9Y3B4 | |
| TAEEMYDIFGKYGPI | 31 | Q9Y3B4 | |
| LDSDYFKYPLMALGE | 536 | O95155 | |
| ELGLPKMEVFQEYYG | 591 | P15498 | |
| YREDGVTPYMIFFKD | 151 | P13693 | |
| LFGMPEEEKLVNYYS | 151 | Q6ZT07 | |
| KYEEVMAVLGSFPYV | 431 | Q9UGP8 | |
| EEILEYNEKTPGYMG | 356 | Q86WI1 | |
| VDPETGKEMSVYEAY | 4281 | Q15149 | |
| PLRGVMEKSFLEYYD | 266 | Q9H832 | |
| GFKMYPIDFEKDDDS | 841 | P22314 | |
| YGPEENLEDDMYRKT | 246 | P23025 | |
| PVDEMGIIRLFYFYK | 161 | Q6P2C0 | |
| KMYGDLDVLFLTDEY | 321 | Q8N806 | |
| MVSEPLEDVDPYYYK | 61 | Q01118 | |
| GFMEFYTKEGEPYLR | 91 | Q9BZW4 | |
| YEEFMPTDGTDVKVY | 236 | O43314 | |
| MDTDLYDEFGNYIGP | 1 | Q15029 | |
| YKYPEGSPEERAVFM | 446 | Q96PF1 | |
| DYPSKMEYFFDPDVL | 1321 | Q5VYS8 | |
| ELGAYVDEELPDYIM | 21 | Q6PJT7 | |
| FLKEYMEEEIPKNYS | 1731 | Q9Y4A5 | |
| YYFDHEAPFGPEEMK | 386 | Q5QJ74 | |
| NEYGDDMYGPEKFTD | 66 | Q9NXG2 | |
| YDLKVPRDMAYVFGG | 501 | Q9H267 | |
| IVQEYIEKPFLMEGY | 186 | Q6ZT98 | |
| PYFGEKEIEMYQGAA | 66 | Q12965 | |
| DEYKLGDPEELMFQY | 341 | Q14CX7 |